Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …

PURPOSE To assess the benefits of epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation …

Abstract The Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis and the meta-
analysis of individual participant data reported by non-small cell lung cancer (NSCLC) Meta …

EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …

Background The optimal neoadjuvant regimen for locally advanced resectable non-small
cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly …

Background Neoadjuvant erlotinib and customized adjuvant therapy are appealing but
controversial. The purpose of this study was to evaluate the role of biomarker-guided …

Introduction Currently, limited data on tyrosine kinase inhibitors as neoadjuvant therapy
exist. This prospective study aimed to investigate the efficacy and safety of preoperative …

Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …

Purpose The development of targeted therapy has introduced new options to improve
treatment outcome in selected patients. The objective of this prospective study was to …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show
great efficacy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR …